Meeting
2020 ASCO Virtual Scientific Program
Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).
Authors
Annick Desjardins
Duke University Medical Center, Durham, NC
Annick Desjardins , Dina Randazzo , Vidyalakshmi Chandramohan , Katherine B. Peters , Margaret O Johnson , Stevie Threatt , Chevelle A Bullock , James Emmett Herndon II, Patrick Healy , Eric S Lipp , John H. Sampson , Allan H. Friedman , Henry S. Friedman , David M. Ashley , Darell D. Bigner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02303678
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2566)
DOI
10.1200/JCO.2020.38.15_suppl.2566
Abstract #
2566
Poster Bd #
57
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Accelerator-based BNCT in rescue treatment of patients with recurrent GBM: A multicenter phase II study.
First Author: Shin-Ichi Miyatake
Poster
2019 ASCO Annual Meeting
Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.
First Author: Annick Desjardins
Poster
2016 ASCO Annual Meeting
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
First Author: Kent C. Shih
Poster
2016 ASCO Annual Meeting
Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.
First Author: Annick Desjardins